论文期刊

取消

高级检索

检索历史清除

首页> PloS one> Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

导出 OA

翻译打印收藏纠错

作者： Vaclava,Polivkova ^[1] ; Peter,Rohon ^[2] ; Hana,Klamova ^[3] ; Olga,Cerna ^[1] ; Martina,Divoka ^[4] ; Nikola,Curik ^[5] ; Jan,Zach ^[3] ; Martin,Novak ^[1] ; Iuri,Marinov ^[1] ; Simona,Soverini ^[3] ; Edgar,Faber ^[1] ; Katerina,Machova Polakova ^[6]

作者单位： Institute of Hematology and Blood Transfusion, Prague, Czech Republic. ^[1] Faculty of Science, Charles University, Prague, Czech Republic. ^[2] Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic. ^[3] Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University, Prague, Czech Republic. ^[4] Department of Internal Medicine and Hematology, 3rd Faculty of Medicine and Faculty Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic. ^[5] Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy. ^[6]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);女(雌)性(Female);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);高通量核苷酸序列分析(High-Throughput Nucleotide Sequencing);人类(Humans);干扰素α(Interferon-alpha);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);男(雄)性(Male);中年人(Middle Aged);蛋白激酶抑制剂(Protein Kinase Inhibitors);治疗结果(Treatment Outcome);青年人(Young Adult)

DOI 10.1371/journal.pone.0155959

PMID 27214026

发布时间 2018-11-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览28

PloS one

PloS one

2016年11卷5期

e0155959页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷